drugset / Trial / NCT02136797

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02136797 ↗

Phase 2 Completed 77 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection. A transfusion is the process by which blood from one person is transferred to the blood of another. In this case, the T-cells are made from the blood of donors who are immune to CMV. The T-cells are then grown and taught to attack the CMV virus in a lab.

Timeline

Start
2014-05-08
Primary completion
2024-02-08
Completion
2024-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CMVpp65 Specific T-cells Cell therapy 1e+06 cells/kg Intravenous